Time Is On Eisai’s Side As More Long-Term Data Emerge For Leqembi
Dual Action Stands Out From Lilly’s Kisunla
Leqembi for early Alzheimer’s disease now has an anti-amyloid competitor in the US with limited-term dosing, but new data at AAIC support chronic dosing of Eisai’s Biogen-partnered drug.
